Evidence mapPaperPMID 29441713Full record

ReviewJournal of cellular and molecular medicine2018

Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.

Chen Zhao, Jeffrey S Isenberg, Aleksander S Popel

Open access · goldAbstract readReview
In one paragraph

Review in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Nutrition and Aging.International journal of molecular sciences · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Functions of Thrombospondin-1 in the Tumor Microenvironment.International journal of molecular sciences · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Chen ZhaoDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-1361-8419
Jeffrey S IsenbergDivision of Pulmonary, Allergy and Critical Care, Department of Medicine, Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Aleksander S PopelDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · USUniversity of Pittsburgh · US

Funding

NCI NIH HHS R01 CA138264NHLBI NIH HHS P01 HL103455NHLBI NIH HHS R01 HL101200NHLBI NIH HHS R01 HL108954NHLBI NIH HHS R01 HL112914NHLBI NIH HHS R21 HL122721
6 · The paper itself

Abstract

Thrombospondin-1 (TSP-1), a matricellular protein and one of the first endogenous anti-angiogenic molecules identified, has long been considered a potent modulator of human diseases. While the therapeutic effect of TSP-1 to suppress cancer was investigated in both research and clinical settings, the mechanisms of how TSP-1 is regulated in cancer remain elusive, and the scientific answers to the question of whether TSP-1 expressions can be utilized as diagnostic or prognostic marker for patients with cancer are largely inconsistent. Moreover, TSP-1 plays crucial functions in angiogenesis, inflammation and tissue remodelling, which are essential biological processes in the progression of many cardiovascular diseases, and therefore, its dysregulated expressions in such conditions may have therapeutic significance. Herein, we critically analysed the literature pertaining to TSP-1 expression in circulating blood and pathological tissues in various types of cancer as well as cardiovascular and inflammation-related diseases in humans. We compare the secretion rates of TSP-1 by different cancer and non-cancer cells and discuss the potential connection between the expression changes of TSP-1 and vascular endothelial growth factor (VEGF) observed in patients with cancer. Moreover, the pattern and emerging significance of TSP-1 profiles in cardiovascular disease, such as peripheral arterial disease, diabetes and other related non-cancer disorders, are highlighted. The analysis of published TSP-1 data presented in this review may have implications for the future exploration of novel TSP-1-based treatment strategies for cancer and cardiovascular-related diseases.

Indexed as

DiseaseGene Expression RegulationHumansModels, BiologicalStromal CellsThrombospondin 1Vascular Endothelial Growth FactorsThrombospondin 1Vascular Endothelial Growth Factorsangiogenesiscancercardiovascular diseasematricellularperipheral arterial diseasethrombospondin-1

Identifiers

PMID29441713
PMCPMC5867078
OpenAlexW2792914595

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.